How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review
Open accessThe DOI matches its Crossref record; 90 of the 92 references it cites were found in a registry or an index.
Abstract
We conducted a review of systematic reviews (SRs) and randomized-controlled trials (RCTs) to analyze efficacy and safety of cannabis-based medication in patients with mental disorders. Five data bases were systematically searched (2006-August 2018); 4 SRs (of 11 RCTs) and 14 RCTs (1629 participants) were included. Diagnoses were: dementia, cannabis and opioid dependence, psychoses/schizophrenia, general social anxiety, posttraumatic stress disorder, anorexia nervosa, attention-deficit hyperactivity disorder, and Tourette`s disorder. Outcome variables were too heterogeneous to conduct a meta-analysis. A narrative synthesis method was applied. The study quality was assessed using the risk-of-bias tool and SIGN-checklists. THC- and CBD-based medicines, given as adjunct to pharmaco- and psychotherapy, were associated with improvements of several symptoms of mental disorders, but not with remission. Side effects occurred, but severe adverse effects were mentioned in single cases only. In order to provide reliable treatment recommendations, more and larger RCTs with follow-up assessments, consistent outcome measures and active comparisons are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous systematic reviews have been limited in their coverage of all relevant diseases, but most importantly primarily ignored the fact that medical cannabinoid products—a term that encompasses all plant-derived and synthetic derivatives—differ in their pharmacology [1–5].”
From Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. (2022) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Encyclopedia of Psychology, Vol. 3. · doi:10.1037/10518-009 · Cited by 19,744
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Diagnostic and Statistical Manual of Mental Disorders(DSM)
(2008) · Encyclopedia of Counseling · doi:10.4135/9781412963978.n182 · Cited by 10,830
Research works printed but not linked: 5
- Higgins JPT Green S Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011] 2011 London The Cochrane Collaboration
- Hoch E Friemel C Schneider M Cannabis: Potenzial und Risiko [Cannabis: Potential and Risks] 2018 Heidelberg Springer
- National Research C, Institute of Medicine Committee on the Prevention of Mental D, Substance Abuse Among Children Y, Young Adults: Research A, Promising I (2009) The National Academies Collection: Reports funded by National Institutes of Health. In: O’Connell ME, Boat T, Warner KE (eds) Preventing mental, emotional, and behavioral disorders among young people: progress and possibilities. National Academies Press (US) 20662125
- OCEBM The oxford levels of evidence 2011 2 Oxford Oxford Centre for Evidence-Based Medicine
- W orld Health Organization ICD-10: international statistical classification of diseases and related health problems/World Health Organization 2004 Geneva World Health Organization
Cited by
Items 101–131 of 131
Consumption of Cannabis: A Risk Factor or a Therapeutic Agent for Patients with Schizophrenia
Zainab, A., Shabbir, D., Waqar, K., & Mehmood, A. (2023) · Springer eBooks · doi:10.1007/978-981-19-7022-1_15
Rometsch, C., Ott, S. J., Wietek, T. F., Jurjut, A.-M., Schlisio, B., Zipfel, S., Stengel, A., & Herrmann‐Werner, A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1033020 · Cited by 1
“Assessments of mental disorders and determinants as psychosomatic and psychosocial variables that may influence cannabis-based treatment remain rare (38), despite considerable interest in the effectiveness of medical cannabis and mental health (39).”
BackgroundMajor approaches to cannabidiol in the treatment of binge eating and obesity: a systematic review
de Lacerda, L. L. M., Ribeiro, D. D. S., Filho, V. C. D. S., Andrade, M. C. S., & de Santana, J. P. C. (2023) · International Journal of Nutrology · doi:10.54448/ijn23208
Disorders Due to Substance Use: Cannabis
Cousijn, J., Compton, W. M., & LEVIN, F. R. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_161-1
von Bodelschwingh, C. (2023) · ASU Arbeitsmedizin Sozialmedizin Umweltmedizin · doi:10.17147/asu-1-316849
Les données probantes et les recommandations sur le cannabis à des fins médicales chez les enfants
Kelly, L. E., Rieder, M. J., & Finkelstein, Y. (2024) · Paediatrics & Child Health · doi:10.1093/pch/pxad077
Emerging therapeutic role of cannabis in neurological disorders
Bisht, A., Jain, S., Dwivedi, J., & Sharma, S. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15489-8.00005-0
Ramarushton, B. (2024) · University of North Texas Digital Library (University of North Texas) · doi:10.12794/metadc2332656
Disorders due to Substance Use: Cannabis
Cousijn, J., Compton, W. M., & LEVIN, F. R. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_161
Іванова, О. (2024) · Bulletin of Taras Shevchenko National University of Kyiv Psychology · doi:10.17721/bpsy.2024.1(19).3
Thiessen, K. A., & Schütz, C. G. (2024) · Cannabis · doi:10.26828/cannabis/2024/000258
“Cannabinoids have been proposed by some as a potential therapeutic for a range of psychiatric disorders and related symptoms (Hoch et al., 2019; Lowe et al., 2018; Sarris et al., 2020; Stith et al., 2020).”
Efectos terapéuticos de los componentes del cannabis
Unzueta‐Larrinaga, P., Urigüen, L., & Callado, L. F. (2025) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2024.10.008
Gliksberg, O., Hulaihel, A., Sznitman, S., Brill, S., Amit, B. H., Lev-Ran, S., Kushnir, T., & Feingold, D. (2025) · Qualitative Health Research · doi:10.1177/10497323251361328
Ritual to Relief: Ethical Frontiers in Repurposing Psychoactive Substances
O’Leary, E., Dodd, S., & Stahl, S. M. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009585330.003
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517185
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517173
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517164
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517176
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517179
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517167
Lucas, P., Boyd, S. C., Milloy, M.-J., & Walsh, Z. (2021) · Figshare · doi:10.6084/m9.figshare.15071182
Orjuela-Rojas, J. M., García Orjuela, X., & Ocampo-Serna, S. (2021) · Figshare · doi:10.6084/m9.figshare.14913815
O uso dos compostos da cannabis para farmacoterapia da doença de Gilles de la Tourette
Antonini, S., AGUIAR, M. H. R., & Ferreira, E. D. F. (2025) · Arquivos do Mudi · doi:10.4025/arqmudi.v30i1.77730
Burdan, O., Picheta, N., Piekarz, J., Gajewski, F. K., Kurec, G., & Szklener, K. (2025) · Current Problems of Psychiatry · doi:10.12923/2353-8627/2025-0014
Censo, G. D., Thompson, K. R., & Bowden, J. A. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113057
Clinical Experience and Student Support for Medical Cannabis Use: A Secondary Analysis
Tong, A. W., DuBoux, C. J., Seuferer, R. H., Clobes, T. A., Siu, F. W., Magana, B., Gold, J. M., & Bensing-Ruiz, J. (2026) · Cannabis · doi:10.26828/cannabis/2026/000386
“CBD was also shown to provide positive anxiolytic effects to individuals diagnosed with generalized social anxiety disorder (Hoch et al., 2019).”
Readiness to Use Medicinal Marijuana in the Practices of Polish Family Physicians
Florek-Łuszczki, M., Lachowski, S., Choina, P., Chmielewski, J. P., & Łuszczki, J. J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072670
Love, S., & Armstrong, K. A. (2026) · Journal of Safety Research · doi:10.1016/j.jsr.2026.04.016
Prevalence of Cannabis Use Among Indigenous Populations – A Systematic Review
Bhat, M., Bhat, S., Sardana, D., & Anikeeva, O. (2026) · Substance Use & Misuse · doi:10.1080/10826084.2026.2670614
“…such as pain management for cancer patients in palliative care (Wang et al., 2021), cannabis use disorder is well described; it can increase symptoms of anxiety and depression and is implicated in the onset of schizophrenia and related psychotic disorders (Hasan et al., 2020; Hoch et al., 2019).”
Ahmed, M., Pereira, C. F., Best, L. M., Mahmood, R., George, T. P., Foll, B. L., Boileau, I., & Kloiber, S. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261478615
Metadata
- Authors
- Hoch, E., Niemann, D., von Keller, R., Schneider, M., Friemel, C. M., Preuss, U. W., Hasan, A., & Pogarell, O.
- Affiliations
- LMU Klinikum (DE)
- Martin Luther University Halle-Wittenberg (DE)
- Corresponding author
- Hoch, Eva
- Venue
- European Archives of Psychiatry and Clinical Neuroscience
- Published
- 2019-01-31
- Volume
- 269
- Issue
- 1
- Pages
- 87-105
- ISSN
- 0003-9373 (ISSN-L)
- 0940-1334
- 1433-8491
- PMC
- PMC6595000
- OpenAlex
- W2912950775
- Cited by
- 131
- References
- 92
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 17 · 2023: 22 · 2022: 22 · 2021: 20 · 2020: 18 · 2019: 11
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-04-05)
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- European Archives of Psychiatry and Clinical Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- OPUS (Augsburg University) (submittedVersion, cc-by)
- Funders
- Bundesministerium f?r Gesundheit
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Keywords
- medical cannabis, cannabis-based medicines, mental illness, schizophrenia, psychosis, post-traumatic stress disorder, social anxiety, anorexia nervosa, attention deficit hyperactivity disorder, Tourette syndrome, dementia, THC, CBD, adjunctive therapy, efficacy, safety, adverse effects
- MeSH terms
- Mental Disorders, Cannabidiol, Humans, Dronabinol, Cannabinoid Receptor Modulators, Medical Marijuana
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.